Diabetes drug slows kidney function decline
McBrayer Attorneys Named to Best Lawyers® in America List for 2022
6 November 2021New COVID vaccine design is easier to manufacture, doesn’t need cold storage
6 November 2021Diabetes drug slows kidney function decline
Clinical trial data reveal that dapagliflozin— a sodium-glucose cotransporter 2 inhibitor prescribed to treat diabetes—reduces the rate of kidney function decline in patients with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2021 November 4–November 7.
